Dr. Horn on Monitoring Response and Resistance to Ensartinib in ALK+ NSCLC
April 11th 2019Leora Horn, MD, MSc, associate professor of cancer research, Vanderbilt University Medical Center, discusses the use of circulating tumor DNA analysis as a means to monitor response to, as well as resistance to, ensartinib in patients with ALK–positive non–small cell lung cancer.
Read More
Dr. Horn on Incorporating T790M-Mutant NSCLC Agents Into NCCN Guidelines
April 2nd 2016Leora Horn, MD, MSc, clinical director, Thoracic Oncology Program, assistant vice chancellor for faculty development, Vanderbilt-Ingram Cancer Center, provides her thoughts on how agents targeted T790M-mutant NSCLC will be incorporated into NCCN guidelines.
Read More